About iX Biopharma

iX Biopharma was formed in Singapore in 2008, when we acquired intellectual property rights of a formulation for a fentanyl citrate nasal spray for patient-controlled analgesia.

Our Company’s founder, Chairman and CEO, Mr Eddy Lee, then recruited a team of scientists with more than 100 years of expertise in drug development between them, to undertake research in the development of an innovative drug delivery system. This would enable the drugs to be delivered safely, with improved efficacy, ease of use and rate of absorption over existing drug delivery platforms and routes of administration.

Today, iX Biopharma is a Singapore public-listed specialty pharmaceutical company with a keen focus on the development and commercialisation of innovative therapies that improve the quality of life for those suffering from pain and other health conditions.

Our Group

Board of Directors

Mr Eddy Lee

Chairman & Chief Executive Officer

Eddy Lee was appointed to the Board on 17 January 2008 and is a member of the Nominating Committee. As Group Chairman & CEO, he is responsible for the development and execution of the Group’s strategic vision and expansion plans.

Eddy possesses more than 25 years of international business experience, having worked as Senior Vice President of Resorts World (Genting Group) in Malaysia, Chief Executive of CDL Hotels International Limited (Hong Leong Group) in Hong Kong, President & Chief Executive of Star Cruises PLC (Genting Group) in Singapore and more recently, as Managing Director & Chief Executive of Amcom Telecommunications Limited in Australia.

Eddy is highly regarded as a professional start-up specialist with a very impressive track record in developing companies that have experienced outstanding brand recognition and tremendous growth. He was involved in the successful start-ups of the Burswood Resort Hotel in Perth and Star Cruises PLC in Singapore, and is perhaps best known for successfully introducing, developing and transforming the cruise industry in Asia into a multi-million dollar business today.

Eddy holds a Bachelor of Business degree from Curtin University.

Mr Albert Ho

Non-Executive Director

Albert Ho was appointed to the Board on 1 March 2013 and serves as a member of the Audit, Remuneration and Risk Management Committees.

Albert is currently a director of Centrum Capital, an investment and asset management firm. He has previously worked at international banks and multinational corporations, and possesses more than 25 years of experience in the areas of corporate development, finance and investment banking.

Albert is also an independent director of Riverstone Holdings Limited, a company listed on the Singapore Exchange, and is a member of its Audit and Remuneration Committees. He is also a Councillor of CPA Australia’s Singapore Division and the Deputy Chairman of CPA Australia’s Corporate-SME Committee in Singapore.

Albert holds a Bachelor of Commerce degree from the Australian National University and is a Fellow Certified Practising Accountant with CPA Australia.

Mr Low Weng Keong

Independent Director

Low Weng Keong was appointed to the Board on 18 June 2015 and serves as the Chairman of the Audit Committee and a member of the Nominating, Remuneration and Risk Management Committees. He is an independent director of UOL Group Limited and Riverstone Holdings Limited, both listed on the Singapore Exchange.

Weng Keong was a former country managing partner of Ernst & Young Singapore and a former Global Chairman and President of CPA Australia. He is a Director of the Confederation of Asian and Pacific Accountants and the Singapore Institute of Accredited Tax Practitioners. He is also a member of the Board of Trustees of the NTUC Education and Training Fund.

Weng Keong is a Life Member of CPA Australia, Fellow Chartered Accountant (UK), Fellow Chartered Accountant (Singapore), life member of CPA (Australia), Chartered Tax Advisor (UK) and an Accredited Tax Advisor (Singapore).

Mr Patrick Davies

Lead Independent Director

Patrick Davies was appointed to the Board on 2 December 2019 and serves as the Lead Independent Director, the Chairman of Remuneration Committee, and a member of Audit and Nominating Committees. Mr. Davies is the Non-Executive Chairman of Nueren Pharmaceuticals Limited listed on the Australian Stock Exchange.

Mr. Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty-five years having performed successfully in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa A$450M to in excess of A$3.1B). He is also a director on other non-listed corporate boards and provides strategic advice to a range of healthcare businesses and investors.

Mr. Davies holds Bachelor of Economics from University of Adelaide and Master of Business Administration from Australian Graduate School of Management.

Ms Claudia Teo

Independent Director

Claudia Teo was appointed to the Board on 18 June 2015 and serves as Chairman of the Nominating and Risk Management Committees, and a member of the Audit and Remuneration Committees. Ms Teo currently heads the Corporate and Financial Services practice group in Eversheds Harry Elias LLP (“EHE”). She possesses over 20 years of experience in corporate and securities laws, advising on landmark, cross- border, merger and acquisition transactions in addition to initial public offerings and compliance issues on the Singapore Stock Exchange. Some of her complex deal structures have focused on various industries including healthcare and pharmaceuticals, fintech, natural resources, lifestyle and real estate and construction.

Claudia’s key practice areas at EHE are corporate finance as well as merger and acquisition transactions throughout Asia. She was recommended in the 2016 edition of The Legal 500 as well as in the 2014 edition of Asialaw’s Leading Publication. She is also a director and member of the Investment/Governance & Risk Committee of Ren Ci Hospital & Medicare Centre, a Singapore charity healthcare institution.

Claudia completed her Bachelor of Laws at University of Manchester. She was called to the Singapore Bar and is dually qualified as a barrister and a solicitor of England and Wales and is admitted to the Rolls of Solicitors of Hong Kong.

Management Team

Mr Eddy Lee

Chairman & Chief Executive Officer

Eddy Lee was appointed to the Board on 17 January 2008 and is a member of the Nominating Committee. As Group Chairman & CEO, he is responsible for the development and execution of the Group’s strategic vision and expansion plans.

Eddy possesses more than 25 years of international business experience, having worked as Senior Vice President of Resorts World (Genting Group) in Malaysia, Chief Executive of CDL Hotels International Limited (Hong Leong Group) in Hong Kong, President & Chief Executive of Star Cruises PLC (Genting Group) in Singapore and more recently, as Managing Director & Chief Executive of Amcom Telecommunications Limited in Australia.

Eddy is highly regarded as a professional start-up specialist with a very impressive track record in developing companies that have experienced outstanding brand recognition and tremendous growth. He was involved in the successful start-ups of the Burswood Resort Hotel in Perth and Star Cruises PLC in Singapore, and is perhaps best known for successfully introducing, developing and transforming the cruise industry in Asia into a multi-million dollar business today.

Eddy holds a Bachelor of Business degree from Curtin University.

Dr Janakan Krishnarajah

Chief Operating Officer & Chief Medical Officer

Dr Janakan Krishnarajah joined iX Biopharma as Chief Medical Officer in April 2016 and was subsequently designated as Chief Operating Officer on 1 April 2019. As Chief Operating Officer and Chief Medical Officer, he is responsible for iX Biopharma’s pharmaceutical and nutraceutical product development, including the design and implementation of clinical trial programmes. He also oversees the operations of the Group’s wholly-owned certified GMP manufacturing facility in Australia.

Prior to joining iX, Dr Krishnarajah was the CEO and Medical Director of Linear Clinical Research Ltd, a leading Australian early phase clinical trials facility. He has extensive experience in phase I-IV clinical trials and has acted as Principal or Co-Investigator in over 100 Phase I/II clinical trials.

Dr Krishnarajah graduated with a Bachelor of Medicine, Bachelor of Surgery (Hons) from The University of Western Australia in 2001. He is a Fellow of the Royal Australasian College of Physicians with specialist interests in Clinical Pharmacology and Internal Medicine and worked as a Consultant Physician in Western Australia.

Mr Yee Chia Hsing

Director of Corporate Affairs / General Manager of Entity Health

As the Director of Corporate Affairs, Chia Hsing is responsible for the development and execution of the Group’s corporate strategies across all segments. He is also concurrently General Manager of our Entity Health nutraceutical business.

Chia Hsing has over 25 years of investment banking and securities industry experience. He has brought more than 20 companies to IPO throughout his career at DBS Bank, Vickers Ballas, GK Goh and CIMB Bank.

Chia Hsing graduated with a Bachelor of Accountancy Degree (First Class Honours) from the Nanyang Technological University, Singapore. He currently sits on the audit committee of Ren Ci Hospital (a Singapore charity) and is an independent director of First Sponsor Group Limited.

Chia Hsing was an elected Member of Parliament for Chua Chu Kang GRC up to June 2020.

Ms Eva Tan

Chief Commercial Officer

As the Chief Commercial Officer, Eva Tan is responsible for the development and execution of the Group’s global commercial strategies across all segments.

Prior to joining iX, Eva was a corporate lawyer at Wong Partnership, a leading law firm in Singapore, where she specialised in the capital markets practice. Eva was involved in numerous local and international IPOs, including the listing of iX Biopharma Ltd on the SGX Catalist in 2015. She has also had extensive experience advising on a broad range of local and cross border mergers and acquisitions and other corporate transactions.

Eva obtained her LLB from the National University of Singapore and was admitted to the Singapore Bar in 2008.

Mr Chew Sien Lup

Chief Financial Officer

Chew Sien Lup joined iX Biopharma in April 2016. As Chief Financial Officer, Sien Lup oversees the accounting, financial, taxation, investment and other financial matters of the iX Group.

Sien Lup has over 20 years of experience holding senior positions responsible for accounting, audit and treasury matters. He spent more than 9 years with an international public accounting firm serving a variety of clients including those in the energy, utilities and high tech industries. Prior to joining iX, he also served as CFO for Singapore eDevelopment Limited and Metech International Limited, both listed on SGX-ST.

Sien Lup graduated from Monash University, Australia in 1988 with a Bachelor of Economics (Accounting) and a Bachelor of Science (Computer Science) Hons. He has been a Certified Practising Accountant of CPA Australia since 1993.

Dr Iain Cook

Chief Scientist

Dr Iain Cook has more than 30 years of experience in the analysis of complex pharmaceutical and biological samples, with a background in pharmaceutical, veterinary, industrial and agrichemical industries.

Prior to his appointment as Chief Scientist at iX Biopharma, Iain was the director of Chemical Analysis Pty Ltd. He also served as analytical chemist at ICI/Orica, where he specialised in nuclear magnetic resonance and led its Spectroscopy Group (NMR/FTIR/SEM-EDXA/NIR), and at PROBE Analytical thereafter.

Iain obtained his Doctor of Philosophy in Nuclear Magnetic Resonance and Synthetic Organic Chemistry from La Trobe University.

Dr Stephen Lim

Chief Pharmacist

Dr Stephen Lim is an Adjunct Professor in the School of Pharmacy at Curtin University and has more than 35 years experience in the hospital and commercial pharmacy sectors. His interest is mainly in research, drug safety and drug delivery, especially in the area of needle-less systems.

Dr Lim is also an expert in drug storage and extending the shelf-life of medication. He completed his Master thesis by looking at drug stability in the frozen state and has shown that intranasal fentanyl delivery is as effective as intravenous fentanyl.

Dr Lim obtained a Bachelor of Pharmacy (with distinctions), a Master of Pharmacy and a Ph.D. in Pharmacy in novel, drug delivery system from Curtin University.

Ms Desiree Chua

Director, Business Development

Desiree Chua is responsible for the business development and marketing activities of the Group’s products in the Asia Pacific region. These include product branding, regulatory affairs, and market research activities. She was previously a management consultant at PricewaterhouseCoopers Singapore before joining iX Biopharma in September 2015.

Desiree obtained her degrees in Bachelor of Business Management and Bachelor of Accountancy at Singapore Management University.

Scientific Advisors

Professor Stephan Schug

Professor Stephan Schug is currently Professor and Chair of Anaesthesiology in the School of Medicine and Pharmacology at the University of Western Australia and Director of Pain Medicine at the Royal Perth Hospital, Australia. He also maintains a position as Honorary Professor of Anaesthesiology at the University of Auckland, New Zealand.

Prof Schug studied Medicine at the University of Cologne, Germany, where he also obtained his MD by thesis in clinical pharmacology and subsequently specialised in anaesthesia, intensive care and pain medicine.

Very early in his career, he focussed his clinical and research interests on the treatment of patients in pain.

In Prof Schug's current position as Director of Pain Medicine in the Department of Anaesthesia and Pain Medicine of Royal Perth Hospital, his clinical responsibilities include running of a Comprehensive Inpatient Pain Service at two sites of this hospital as well as a multi-disciplinary Pain Medicine Centre, which is accredited for training by the Faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists.

Dr Bob Rappaport, MD

Dr Bob Rappaport joined the neurology division at US FDA’s Center for Drug Evaluation and Research in 1994, where he spent a few years developing expertise in drug regulatory science, drug product development, and clinical trial design and analysis. He was promoted to Deputy Division Director of the FDA Division of Anesthesia, Analgesia, and Addiction Products in 1998. In 2002, he was appointed Director of the same Division, where he remained until his retirement in October 2014.

Throughout his tenure, he was an advocate for the development of novel analgesic, anesthetic and addiction drug products, and instituted new standards for the study of these drugs. Dr Rappaport was also a key player in the FDA’s continued efforts to encourage and assist the development of abuse-deterrent opioid formulations, and oversaw the updated guidance on the development of analgesic drug products.

In 2013, Dr Rappaport received FDA’s Lifetime Achievement Award for his work in advancing the fields of anesthesia, analgesia and addiction. In May 2015, he received the 2015 John and Emma Bonica Public Service Award from the American Pain Society, which recognises distinguished contributions to the field of pain through public services or other efforts that further knowledge about pain.

Dr Rappaport completed his medical training at The George Washington University School of Medicine and Health Sciences, and is board certified in neurology and sleep medicine.

Emeritus Professor Vivian Bruce Sunderland

Professor Bruce Sunderland is the Emeritus Professor at the School of Pharmacy, Curtin University of Technology in Perth, Western Australia where he specialises in drug delivery and drug stability research areas.

Prof Sunderland has over 40 years experience as an academic pharmacist, teaching and researching in physical pharmacy, pharmaceutical technology and medicine formulation. He has been involved in supervising a broad range of research projects, including implant drug delivery systems and drug stability. He has published over 130 research publications in peer-reviewed journals.

Prof Sunderland holds a Bachelor of Pharmacy from Curtin University, a Postgraduate Diploma in Pharmaceutical Technology from the University of London and a Doctor of Philosophy from the University of Western Australia. He is a Fellow of the Pharmaceutical Society of Australia and a Member of the Society of Hospital Pharmacists of Australia (Honoris Causa).

Dr Yandi Liu

Dr Yandi Liu has been working in pharmaceutical research areas for more than 30 years and has accumulated a wealth of expertise from both industry and university laboratories.

His research interests include controlled drug delivery systems, pharmacology and toxicology of natural products, mass spectrometry of bioactive molecules, analytical and structure biochemistry.

Dr Liu has a Bachelor of Science (Pharmacy) from Henan University, China (1986), and obtained his PhD from Curtin University of Technology, Western Australia. He is currently an honorary Research Fellow with the School of Pharmacy at Curtin University.